Randomized, 4-Way, Crossover Single Dose, Placebo And Active Controlled Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects.

Trial Profile

Randomized, 4-Way, Crossover Single Dose, Placebo And Active Controlled Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2013

At a glance

  • Drugs Tigecycline (Primary) ; Moxifloxacin
  • Indications Bacterial infections; Community-acquired pneumonia; Intra-abdominal infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 20 Apr 2012 Results presented at the 113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 23 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Mar 2011 Planned end date changed from 1 Jun 2011 to 1 May 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top